Compare STRA & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRA | BCRX |
|---|---|---|
| Founded | 2017 | 1986 |
| Country | United States | United States |
| Employees | N/A | 435 |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 1996 | 1995 |
| Metric | STRA | BCRX |
|---|---|---|
| Price | $80.45 | $8.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $87.00 | $20.82 |
| AVG Volume (30 Days) | 206.0K | ★ 4.4M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | 15.85 | ★ 381.40 |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $997,137,000.00 | $25,186,000.00 |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $4.67 | $12.55 |
| P/E Ratio | $55.08 | ★ N/A |
| Revenue Growth | ★ 57.23 | N/A |
| 52 Week Low | $69.70 | $6.00 |
| 52 Week High | $88.50 | $10.46 |
| Indicator | STRA | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 48.66 |
| Support Level | $78.96 | $7.95 |
| Resistance Level | $84.09 | $9.31 |
| Average True Range (ATR) | 2.00 | 0.34 |
| MACD | 0.31 | -0.01 |
| Stochastic Oscillator | 66.33 | 45.73 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.